IDH2 and astrocytoma (excluding glioblastoma): The presence of cyclin-dependent kinase inhibitor (CDKN) 2A/B homozygous deletion, even in the absence of microvascular proliferation or necrosis, portends a worse prognosis and therefore is classified as astrocytoma, IDH-mutant, CNS WHO grade 4.